GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Green Cross Corp (XKRX:006280) » Definitions » Total Liabilities

Green Cross (XKRX:006280) Total Liabilities : ₩1,262,860 Mil (As of Dec. 2024)


View and export this data going back to 1989. Start your Free Trial

What is Green Cross Total Liabilities?

Green Cross's Total Liabilities for the quarter that ended in Dec. 2024 was ₩1,262,860 Mil.

Green Cross's quarterly Total Liabilities increased from Jun. 2024 (₩1,241,423.70 Mil) to Sep. 2024 (₩1,271,786.55 Mil) but then declined from Sep. 2024 (₩1,271,786.55 Mil) to Dec. 2024 (₩1,262,860.15 Mil).

Green Cross's annual Total Liabilities increased from Dec. 2022 (₩958,895.15 Mil) to Dec. 2023 (₩1,103,450.61 Mil) and increased from Dec. 2023 (₩1,103,450.61 Mil) to Dec. 2024 (₩1,262,860.15 Mil).


Green Cross Total Liabilities Historical Data

The historical data trend for Green Cross's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Green Cross Total Liabilities Chart

Green Cross Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 882,093.85 962,387.72 958,895.15 1,103,450.61 1,262,860.15

Green Cross Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,103,450.61 1,190,787.73 1,241,423.70 1,271,786.55 1,262,860.15

Green Cross Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Green Cross's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=769474.795+(435917.481+39985.249
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+16805.083+677.538)
=1,262,860

Total Liabilities=Total Assets (A: Dec. 2024 )-Total Equity (A: Dec. 2024 )
=2743875.852-1481015.706
=1,262,860

Green Cross's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=769474.795+(435917.481+39985.249
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+16805.083+677.538)
=1,262,860

Total Liabilities=Total Assets (Q: Dec. 2024 )-Total Equity (Q: Dec. 2024 )
=2743875.852-1481015.706
=1,262,860

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Green Cross Total Liabilities Related Terms

Thank you for viewing the detailed overview of Green Cross's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Green Cross Business Description

Traded in Other Exchanges
N/A
Address
303 Bojeong-Dong, Giheung-Gu, Yongin, Gyeonggi, KOR, 449-070
Green Cross Corp is one of the global leaders in the healthcare sector. The Montreal-based biopharmaceutical company primarily develops intravenous immunoglobulin (IVIG), a key therapeutic solution for the treatment of patients with infectious and immune diseases, and albumin, used as a blood-volumizing agent and in the treatment of burns. Currently, the company has a global presence through its association with various subsidiaries.

Green Cross Headlines

No Headlines